Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-901 · 1 trial · 1 indication
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment.
Overall response is defined as participants achieving confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by the investigator.
| Arm | Type | Description |
|---|---|---|
| Part 1: ABBV-901 Dose Escalation | EXPERIMENTAL | Participants will receive escalating doses of ABBV-901 alone, as part of the approximately 3 year study duration. |
| Part 2: ABBV-901 Optimization/Expansion Dose A | EXPERIMENTAL | Participants will receive ABBV-901 dose A alone, as part of the approximately 3 year study duration. |
| Part 2: ABBV-901 Optimization/Expansion Dose B | EXPERIMENTAL | Participants will receive ABBV-901 dose B alone, as part of the approximately 3 year study duration. |
| Part 2: ABBV-901 Optimization/Expansion Dose C | EXPERIMENTAL | Participants will receive ABBV-901 dose C alone, as part of the approximately 3 year study duration. |
| Part 3: ABBV-901 + Bevacizumab Escalation | EXPERIMENTAL | Participants will receive escalating doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration. |
| Part 4: ABBV-901 + Bevacizumab Expansion | EXPERIMENTAL | Participants will receive the recommended doses for expansion doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration. |
| Name | Type | Description |
|---|---|---|
| ABBV-901 | DRUG | Intravenous (IV) |
| Bevacizumab | DRUG | IV |
Inclusion Criteria: * Diagnosis of an advanced or unresectable malignant high grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC), fallopian tube or primary peritoneal cancer by histology (World Health Organization \[WHO\] criteria). * Participants must be consider...
Top 20 of 59 competitors
ABBV-901 is an investigational small molecule being studied for the treatment of ovarian cancer. It is currently in Phase 1 clinical development, with an active trial assessing the drug alone or in combination with bevacizumab in adult participants with ovarian cancer. The drug is not yet approved and remains in clinical testing.
ABBV-901 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is currently conducting a Phase 1 clinical trial of ABBV-901 in ovarian cancer.
ABBV-901 is in Phase 1 clinical development. It is an investigational drug being studied for ovarian cancer and has not been approved by regulatory authorities. The ongoing Phase 1 trial is actively recruiting participants.
ABBV-901 is being evaluated in a Phase 1 clinical trial with the identifier NCT07278336. This study assesses adverse events, changes in disease activity, and how intravenous ABBV-901 moves through the body, alone or in combination with bevacizumab, in adult participants with ovarian cancer. The trial is actively recruiting and has a target enrollment of 219 participants.
Yes, ABBV-901 is being studied both alone and in combination with bevacizumab in a Phase 1 clinical trial for ovarian cancer. The trial, NCT07278336, is designed to evaluate the safety and pharmacokinetics of ABBV-901 when given intravenously, either as a monotherapy or combined with bevacizumab.